ABN.AS: $40.75 ▲ 0.30 (0.74%)DSFIR.AS: $99.66 ▼ -0.99 (-0.98%)GMAB.CO: $2,487.00 ▲ 42.00 (1.72%)REP.MC: $29.21 ▼ -0.31 (-1.05%)SOON.SW: $267.80 ▲ 3.20 (1.21%)CRWD: $263.50 ▼ -11.54 (-4.20%)HPE: $70.11 ▼ -3.35 (-4.56%)AMD: $590.61 ▼ -17.49 (-2.88%)DELL: $574.75 ▼ -11.31 (-1.93%)PANW: $400.24 ▼ -18.54 (-4.43%)MRNA: $214.31 ▼ -10.69 (-4.75%)AAPL: $339.43 ▲ 2.79 (0.83%)AMZN: $259.99 ▼ -2.44 (-0.93%)MSFT: $539.91 ▲ 4.84 (0.90%)NVDA: $226.49 ▼ -2.79 (-1.22%)CIEN: $402.89 ▼ -46.88 (-10.42%)DDOG: $288.37 ▼ -4.89 (-1.67%)SNPS: $503.27 ▼ -6.72 (-1.32%)CAP.PA: $115.35 ▲ 0.30 (0.26%)TSCO.L: $511.00 ▲ 7.20 (1.43%)WKL.AS: $77.16 ▲ 2.16 (2.88%)

Company Details

Eterna Therapeutics Inc.

ERNA - NASDAQ

Identifiants & Marche

Ticker ERNA
ISIN US1140822099
CIK 0000748592
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Voir l'evolution du cours Retour